ArticleJournal of clinical medicine2021
Chemically-Boosted Corneal Cross-Linking for the Treatment of Keratoconus through a Riboflavin 0.25% Optimized Solution with High Superoxide Anion Release.
Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 17 citations in OpenAlex.
- Imbalance of Pro-Oxidant and Anti-Oxidant Biomarkers in Patients with Keratoconus.Antioxidants (Basel, Switzerland) · 2026Article
- Digital transformation of care for keratoconus patients: ML modeling structural outcomes of corneal collagen cross-linking.Frontiers in medicine · 2025Article
- Influencing Factors in Corneal Densitometry Recovery After Accelerated Cross-Linking for Keratoconus.Journal of ophthalmology · 2025Article
- Mendelian Randomisation Analysis of Causal Association between Lifestyle, Health Factors, and Keratoconus.Bioengineering (Basel, Switzerland) · 2024Article
- Results of the Pinhole Test Correlate with Hybrid Contact Lens Visual Acuity in Patients with Visual Impairment due to Corneal Diseases.Journal of ophthalmology · 2022Article
- Continuous Intracorneal Ring Implantation in Keratoconus: Efficacy, Predictive Factors, and Complications.Clinical ophthalmology (Auckland, N.Z.) · 2022Article
- Comparison of Long-Term Outcomes and Refractive Stability following SMILE versus SMILE Combined with Accelerated Cross-Linking (SMILE XTRA).Journal of ophthalmology · 2022Article
- Crosslinking vs. Observation in Fellow Eyes of Keratoconus Patients.Journal of ophthalmology · 2022Article
- Corneal Topographic versus Manifest Refractive Astigmatism in Patients with Keratoconus: A Retrospective Cross-Sectional Study.Clinical ophthalmology (Auckland, N.Z.) · 2022Article
- Comparative Results Between "Epi-Off" Accelerated and "Epi-Off" Standard Corneal Collagen Crosslinking-UVA in Progressive Keratoconus - 7 Years of Follow-Up.Therapeutics and clinical risk management · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this study was to evaluate the effectiveness and safety of a novel buffered riboflavin solution approved for corneal cross-linking (CXL) in progressive keratoconus and secondary corneal ectasia. Following the in vivo preclinical study performed on New Zealand rabbits comparing the novel 0.25% riboflavin solution (Safecross
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.